BOARD OF DIRECTORS
Jerel Davis, PhD
Managing Director, Versant Ventures
Jerel is a Managing Director based at Versant Ventures. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups.
He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia and India. Jerel was a post doctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.
Managing Director, MPM Capital
Todd is a Managing Director at MPM Capital. He focuses on biotech investments, and in addition to serving on Repare’s board, he serves on a number of MPM portfolio company boards, including Switch Bio, Chiasma (CHMA), ClinicalInk, Iconic, Rhythm, Semma and Tetherex.
Todd also manages MPM’s strategic investment relationship with Novartis (NVS), which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.
Prior to MPM, Todd’s career in the life science industry included Business Development at Genentech (acquired by Roche) and management consulting with Arthur D. Little. He holds a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Briggs W. Morrison, MD
CEO, Syndax Pharmaceuticals
Briggs is the CEO of Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Dr. Morrison also currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm.
Dr. Morrison previously served as EVP, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility within Merck & Co., Inc., including the role of VP, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison was chairman of the board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, a member of the executive committee of the Clinical Trials Transformation Initiative (CTTI) sponsored by FDA, and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety) and Oncorus, Inc. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut. He completed his training in Internal Medicine at the Massachusetts General Hospital, and training in Medical Oncology at the Dana Farber Cancer Institute.
Lloyd M. Segal
President & CEO, Repare Therapeutics
In addition to his role as Repare’s President & CEO, Lloyd is an Entrepreneur-in-residence at Versant Ventures. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor. Lloyd held CEO roles at Caprion Pharmaceticals, Advanced Bioconcept and Thallion Pharmaceuticals, and has served as a director of several public and private corporations in the U.S. and Canada.
In 2013, Lloyd was honored by the Financial Times as Outstanding Corporate Director of the Year. He currently acts as Chairman of LMC Diabetes & Endocrinology, North America’s largest community endocrinology and diabetes practice, as a member of the Board of GBC American Fund, a US growth-focused mutual fund, and was Board Chairman of MedReleaf Inc. (TSX:LEAF), Canada’s leading medical cannabis provider until its sale to Aurora Cannabis (TSX:ACB) for $3.2 billion in July, 2018.
Lloyd holds a BA from Brandeis University and an MBA from Harvard Business School.